No Data
Sinolink: The end of year centralized purchasing expectations are gradually being cleared, and the pharmaceutical sector行情 is expected to gradually start.
The pharmaceutical Sector is currently in a process of a triple reversal in performance, policies, and funding, with full confidence in the recovery of revenue profit growth and market resurgence of listed companies in the Sector by 2025.
Humanwell Healthcare (600079.SH): Yichang Industrial Investment Group collectively controls 12.35% of the voting shares of the company.
On December 12, Gelonghui reported that Humanwell Healthcare (600079.SH) announced that this equity change involves a 5% or more non-first largest Shareholder, Yichang Chanto Holdings Group Co., Ltd. (referred to as "Yichang Chanto Group"), whose wholly-owned subsidiary is Yichang Chanto Industry Research and Development Co., Ltd. (referred to as "Industry Research Company"), signing the agreement with Xinshenglibao Private Equity Co., Ltd. (referred to as "Xinshenglibao"), CHINA CINDA Asset Management Co., Ltd. (referred to as "CHINA CINDA"), and Yichang Hi-tech Capital Investment Management Co., Ltd. (referred to as "Yichang Hi-tech Capital").
Humanwell Healthcare (600079.SH): Director Wang Xuehai has cumulatively reduced his shareholding by 0.89 million shares of the company.
On December 10, Glonghui reported that Humanwell Healthcare (600079.SH) announced that as of the date of this announcement, the Shareholding plan's Range has expired, and Director Wang Xuehai has cumulatively reduced his holdings by 0.89 million shares, accounting for 0.05% of the company's total equity.
Sinolink Securities: The favorable wind of medical policies arrives first, followed by innovation going abroad and performance reversal.
In 2025, Sinolink believes that the core investment opportunities in the pharmaceutical Sector will revolve around three main logics: 1) innovation going abroad; 2) demand recovery; 3) reversal of policy expectations.
Humanwell Healthcare Unit Gets Nod to Register Ursodeoxycholic Acid Capsules
Humanwell healthcare (600079.SH) announced that the subsidiary's application for the market approval of recombinant plasmid - Hepatocyte Growth Factor injection has been accepted.
Humanwell Healthcare (600079.SH) announced that its holding subsidiary Wuhan Guogu Humanwell Biomedical Co., Ltd....
The Market Doesn't Like What It Sees From Humanwell Healthcare (Group) Co.,Ltd.'s (SHSE:600079) Earnings Yet
No Data
